Drug Trial Radar · NCT02861573
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,200
Planned (sponsor's estimate)
Start
Nov 17, 2016
Primary completion
Oct 22, 2027
Study completion Jul 24, 2028
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Aug 10, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in participants with metastatic castration resistant prostate cancer (mCRPC). There will be ten cohorts in this study: Cohort A will receive pembrolizumab + olaparib, Cohort B will receive pembrolizumab + docetaxel + prednisone, Cohort C will receive pembrolizumab + enzalutamide, Cohort D will receive pembrolizumab + abiraterone + prednisone Cohort E will receive pembrolizumab+lenvatinib, Cohort F will receive pembrolizumab+lenvatinib, Cohort G will receive pembrolizumab/vibostolimab coformulation (MK-7684A), Cohort H will receive pembrolizumab/vibostolimab coformulation, Cohort I will receive pembrolizumab+carboplatin+etoposide in Arm 1 and carboplatin+etoposide in Arm 2 and Cohort J will receive belzutifan in Arm1 and Pembrolizumab+belzutifan in Arm 2. Outcome measures will be assessed individually for each cohort.
Conditions
- Metastatic Castration-Resistant Prostate Cancer
Interventions
Pembrolizumab 200 mgBiological
IV Q3W
Olaparib 400 mgDrug
Eight 50-mg capsules PO BID
Docetaxel 75 mg/m^2Drug
IV Q3W
Prednisone 5 mgDrug
One 5-mg tablet PO BID
Enzalutamide 160 mgDrug
Four 40-mg capsules, four 40-mg tablets, or two 80-mg tablets PO QD
Dexamethasone 8 mgOther
Premedication for Cohort B given PO at 12, 3, and 1 hours prior to docetaxel infusion Q3W
Olaparib 300 mgDrug
Two 150-mg tablets PO BID
Abiraterone acetate 1000 mgDrug
Two 500-mg or four 250-mg tablets PO QD
LenvatinibDrug
20 mg PO QD
Pembrolizumab/Vibostolimab coformulationBiological
IV Q3W
CarboplatinDrug
IV Q3W
EtoposideDrug
IV on Days 1, 2 and 3 of each cycle
Belzutifan 120mgBiological
PO QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a Decrease of ≥50% in Prostatic Specific Antigen (PSA)Time frame: From Baseline Measured Every 3 Weeks Until Radiographic Progression Estimated to be Approximately 2 Years
- Number of Participants with Adverse Events (AEs)Time frame: Assessed Every 3 Weeks Over the Duration of the Study Which is Estimated to be Approximately 2 Years
- Number of Participants Discontinuing Study Drug Due to AEsTime frame: Assessed Every 3 Weeks Over the Duration of the Study Which is Estimated to be Approximately 2 Years
- Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR)Time frame: Assessed Over the Duration of the Study Which is Estimated to be Approximately 2 Years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.